Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Kyoichi Takaori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1536-9049; OpenAlex author ID A5091454068. Sources: OpenAlex.

Their work

Papers
34 (first author 6, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
160
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 4 papers · 2015: 5 papers · 2016: 4 papers · 2017: 4 papers · 2018: 4 papers · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 34

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  3. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  4. Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreat… Co-author DOI 10.1016/j.pan.2022.04.006↗
  5. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Co-author DOI 10.1186/s12885-022-09244-6↗
  6. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Co-author DOI 10.7554/elife.55117↗
  7. Left-posterior approach for artery-first en bloc resection in laparoscopic distal pancreatectomy for left-sided pancreatic cancer. Co-author DOI 10.1007/s00423-020-02021-8↗
  8. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  9. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective… Co-author DOI 10.1016/j.suronc.2020.10.010↗
  10. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. Co-author DOI 10.1136/gutjnl-2017-315425↗
  11. Familial Pancreatic Cancer and Surveillance of High-Risk Individuals. First author DOI 10.5009/gnl18449↗
  12. "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire o… Co-author DOI 10.1016/j.pan.2018.01.004↗
  13. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2018.03.039↗
  14. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1186/s13014-018-1063-5↗
  15. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24865↗
  16. Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries. Co-author DOI 10.1097/mpa.0000000000000891↗
  17. Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6077-y↗
  18. A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement. First author DOI 10.21873/anticanres.12172↗
  19. Familial pancreatic cancer: Concept, management and issues. First author DOI 10.3748/wjg.v23.i6.935↗
  20. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Co-author DOI 10.1007/s00595-016-1310-z↗
  21. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-015-0864-x↗
  22. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.013↗
  23. Pancreatic cancer. Last author DOI 10.1016/s0140-6736(16)00141-0↗
  24. Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.09.016↗
  25. Screening for Pancreatic Cancer. First author DOI 10.1016/j.suc.2015.05.010↗
  26. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.02.002↗
  27. [Familial pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1479↗
  28. [Recent advances in research on familial pancreatic cancer by using the registry]. Co-author PMID 25857059↗
  29. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.204↗
  30. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable progn… Co-author DOI 10.1007/s00066-014-0610-8↗
  31. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  32. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Co-author DOI 10.1097/mpa.0000000000000050↗
  33. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. First author DOI 10.1007/s00534-013-0611-5↗
  34. Laparoscopic common hepatic artery ligation and staging followed by distal pancreatectomy with en bloc resection of celiac artery for advanced pancreatic cance… First author DOI 10.1111/j.1758-5910.2011.00105.x↗

Closest collaborators

The 25 strongest of 160 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shinji Üemoto · 14 shared papers, 2011–2022 · strength 0.89
  2. Toshihiko Masui · 9 shared papers, 2015–2022 · strength 0.69
  3. Masashi Kanai · 9 shared papers, 2014–2022 · strength 0.55
  4. Chigusa Morizane · 3 shared papers, 2017–2022 · strength 0.41
  5. Takashi Mizowaki · 5 shared papers, 2014–2022 · strength 0.39
  6. Tsutomu Chiba · 6 shared papers, 2014–2021 · strength 0.37
  7. Akihisa Fukuda · 4 shared papers, 2018–2022 · strength 0.36
  8. Kazuyuki Nagai · 3 shared papers, 2020–2022 · strength 0.34
  9. Yuzo Kodama · 6 shared papers, 2014–2018 · strength 0.30
  10. Yuichiro Uchida · 3 shared papers, 2017–2022 · strength 0.28
  11. Susumu Hijioka · 2 shared papers, 2017–2022 · strength 0.27
  12. Michio Yoshimura · 3 shared papers, 2014–2022 · strength 0.27
  13. Sohei Satoi · 2 shared papers, 2023 · strength 0.26
  14. Yoo‐Seok Yoon · 2 shared papers, 2023 · strength 0.26
  15. Jin Peng He · 2 shared papers, 2023 · strength 0.26
  16. Masayuki Sho · 2 shared papers, 2023 · strength 0.26
  17. Thilo Hackert · 2 shared papers, 2023 · strength 0.26
  18. Atsushi Oba · 2 shared papers, 2023 · strength 0.26
  19. Daisuke Hashimoto · 2 shared papers, 2023 · strength 0.26
  20. Yoshifumi Takeyama · 2 shared papers, 2023 · strength 0.26
  21. Ippei Matsumoto · 2 shared papers, 2023 · strength 0.26
  22. Jin‐Young Jang · 2 shared papers, 2023 · strength 0.26
  23. Marco Del Chiaro · 2 shared papers, 2023 · strength 0.26
  24. Tsutomu Fujii · 2 shared papers, 2023 · strength 0.26
  25. Kozo Ikuta · 3 shared papers, 2018–2021 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.